Chung-Han Lee1, Amishi Y. Shah2, Vicky Makker1, Matthew Taylor3, David Shaffer4, James J. Hsieh5, Allen L. Cohn6, Chris DiSimone7, Alvaro Pinto Marin8, Drew Rasco9, Sara Gunnestad Ribe10, Donald A. Richards11, Daniel E. Stepan*, Corina E. Dutcus12, Jane Wu12, Emmett V. Schmidt13, Rodolfo Perini13, Robert Motzer1 1Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2MD Anderson Cancer Center, University of Texas, Houston, TX, USA; 3Oregon Health and Science University; Portland, OR, USA; 4New York Oncology Hematology, Albany, NY, USA; 5Washington University School of Medicine, St. Louis, MO, USA; 6Rocky Mountain Cancer Center, Denver, CO, USA; 7Arizona Oncology Associates, Tucson, AZ, USA; 8Hospital Universitario La Paz, Madrid, Spain; 9South Texas Accelerated Research Therapeutics, San Antonio, TX, USA; 10Sorlandet Hospital, Kristiansand, Norway; 11Texas Oncology, US Oncology Research, Tyler, TX, USA; 12Eisai Inc., Woodcliff Lake, NJ, USA; 13Merck & Co. Inc., Kenilworth, NJ, USA. *Formerly of Eisai Inc. 18th International Kidney Cancer Symposium 2019, Miami, FL.
__________
Interview here:Â https://www.oncologytube.com/video/phase-2-study-of-lenvatinib-plus-pembrolizumab-for-disease-progression-after-pd-1-pd-l1